{"id":11435,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:32:07","modified_gmt":"2025-10-04T08:32:07","slug":"hipertermije-kvalitetu-zivota-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/hr\/hipertermije-kvalitetu-zivota-qol\/","title":{"rendered":"Utjecaj hipertermije na kvalitetu \u017eivota (QoL): Ubla\u017eavanje boli, smanjenje umora i adjuvantne imunolo\u0161ke prednosti"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Utjecaj hipertermije na kvalitetu \u017eivota (QoL): Ubla\u017eavanje boli, smanjenje umora i adjuvantne imunolo\u0161ke prednosti\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermija, Onkologija, Faza III klini\u010dko ispitivanje, QoL, bol, E-E-A-T\"\n      \/*... FAQPage Shema bi se dodala zasebno za odjeljak \u010cesto Postavljana Pitanja *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoritet i Stru\u010dnost (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autor: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/hr\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, i <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/hr\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Utjecaj hipertermije na kvalitetu \u017eivota (QoL): Ubla\u017eavanje boli, smanjenje umora i adjuvantne imunolo\u0161ke prednosti<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">U modernoj onkologiji, lije\u010denje raka te\u017ei optimalnoj ravnote\u017ei izme\u0111u<a href=\"https:\/\/andromedichyperthermia.com\/hr\/hipertermija-prezivljenje-pacijenata\/\"> Pre\u017eivljenja (OS\/DFS)<\/a> i <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvalitete \u017divota (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija (HT) predstavlja jedinstvenu adjuvantnu modalitetu, dokazanu kroz velika klini\u010dka ispitivanja ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/hr\/hipertermije-studija-faze-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faza III RCT-ovi<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) da pobolj\u0161ava QoL na vi\u0161e razina: kontrola simptoma, op\u0107e funkcionalno stanje i izvrstan sigurnosni profil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Glavna Palijativna Korist: Kontrola Boli (A1 razina dokaza iz klini\u010dkih ispitivanja Faze III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatska bol u kostima naru\u0161ava QoL. Lokoregionalna RF hipertermija, kombinirana s Radioterapijom (RT), pru\u017ea superiornu palijativnu kontrolu, prema <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">studiji Faze III koju su objavili Chi MS i sur<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Pokazatelj\/Pobolj\u0161anje Boli<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (HT)<\/span><\/span><\/th>\n<th>QoL Utjecaj<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Stopa Potpunog Odgovora (CR) nakon 3 Mjeseca<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulti rezultat boli)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533% pove\u0107anje \u0161ansi za potpuno uklanjanje boli.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje Ubla\u017eavanja Boli<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medijan: 55 dana\/7,9 tjedana<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medijan: Nije dosegnut u 24. tjednu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje ubla\u017eavanja se utrostru\u010duje, smanjuju\u0107i ovisnost o analgeticima.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024. godine <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sahinbas i kolege objavili su studiju Faze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> za bol kod ko\u0161tanih metastaza, uglavnom od raka dojke i prostate, koriste\u0107i WBHT wIRA hipertermiju uz RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na temelju ove studije, grupa tretirana samo radioterapijom (RT) pokazala je najintenzivniju bol. Studija je dovr\u0161ena nakon \u0161to je uklju\u010deno ukupno 61 pacijent, 5 godina nakon prve registracije (travanj 2016. \u2013 velja\u010da 2021.). Kona\u010dno, stopa CR u skupini RT + WBH pokazala je najzna\u010dajniju razliku u odnosu na samo RT, 47,4% naspram 5,3%, u roku od 2 mjeseca nakon tretmana (P-vrijednost &lt; 0,05). Vrijeme do potpunog ubla\u017eavanja boli bilo je 10 dana za RT + WBH, dok krajnja to\u010dka nije dosegnuta u skupini RT monoterapije. Progresija boli ili stabilnost bolesti opa\u017eeni su kod polovice pacijenata u RT skupini unutar 4 tjedna nakon tretmana. Me\u0111utim, ovaj rezultat bio je blizu nule kod pacijenata RT + WBHT unutar dva mjeseca nakon tretmana.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zaklju\u010dci:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT demonstrirali su zna\u010dajno pove\u0107anje ubla\u017eavanja boli i kra\u0107e vrijeme odgovora u usporedbi sa samo RT kod pacijenata s metastatskim ko\u0161tanim lezijama.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Pokazatelj\/Pobolj\u0161anje Boli<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL Utjecaj<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Stopa Potpunog Odgovora (CR) nakon 2 Mjeseca<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulti rezultat boli)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % pove\u0107anje<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * \u0161ansi za potpuno uklanjanje boli.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vrijeme do potpunog ubla\u017eavanja boli<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">nije dosegnuto<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dana<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Zna\u010dajna i Brza Prednost<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje Ubla\u017eavanja Boli\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medijan: 28 dana\/4 tjedna kod polovice pacijenata<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medijan: Nije dosegnut u 24. tjednu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Trajanje ubla\u017eavanja * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">pove\u0107ava se \u0161est puta<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, smanjuju\u0107i ovisnost o analgeticima.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Pobolj\u0161anje Funkcionalnog Statusa i Smanjenje Umora<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Korist od HT-a na QoL izravno je mjerljiva putem standardiziranih upitnika (EORTC QLQ-C30), pokazuju\u0107i pobolj\u0161anje u op\u0107em stanju (Fizi\u010dka Funkcija, Umor i Anksioznost):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zna\u010dajno Pobolj\u0161ana QoL (modulirana RF hipertermija mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomizirano klini\u010dko ispitivanje Modulirane RF Hipertermije (mEHT) kod raka vrata maternice (LACC) izvijestilo je o zna\u010dajnom pobolj\u0161anju dugoro\u010dnih QoL rezultata, pri \u010demu su pacijenti prijavili bolje rezultate na skalama Fizi\u010dke i Emocionalne Funkcije.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kontrola Umora i Imunomodulacija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija Cijelog Tijela (WBHT) i HT op\u0107enito pozitivno utje\u010du na kroni\u010dni umor (CRF) modulacijom proinflamatornih citokina (IL-6, TNF-alfa). HT tako\u0111er poma\u017ee u odr\u017eavanju i pobolj\u0161anju rezultata na skalama Fizi\u010dke i Emocionalne Funkcije dugoro\u010dno.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Brzi Emocionalni Oporavak (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Nakon velikih kirur\u0161kih zahvata koji uklju\u010duju HT (HIPEC), emocionalna QoL obi\u010dno se brzo pobolj\u0161ava, po\u010dev\u0161i ve\u0107 *3 mjeseca nakon operacije, \u010desto nadma\u0161uju\u0107i po\u010detne razine.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolidacija Dugoro\u010dnih QoL Prednosti<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Podaci iz stvarnog \u017eivota i klini\u010dka ispitivanja kod uznapredovalih karcinoma potvr\u0111uju ulogu hipertermije u stabilizaciji i pobolj\u0161anju dugoro\u010dne QoL:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativni Utjecaj nakon 12 Mjeseci:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Opse\u017ena analiza pacijenata lije\u010denih s kurativnom namjerom (RCT + HT) pokazala je zna\u010dajno pobolj\u0161anje, odr\u017eano tijekom *12-mjese\u010dnog razdoblja, u rezultatima na QoL podskalama koje procjenjuju **Emocionalnu Funkciju, Socijalnu Funkciju* i *Nesanicu (SL)*, u usporedbi s onkolo\u0161kom referentnom populacijom EORTC-a .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palijativne Prednosti:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> U palijativnom kontekstu, dodavanje HT-a standardnom lije\u010denju dovelo je do klini\u010dki relevantnog pobolj\u0161anja *Boli (PA)* i smanjenja *Financijskih Pote\u0161ko\u0107a (FI)* *3 mjeseca nakon tretmana*, pridonose\u0107i boljem op\u0107em stanju pacijenta .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pobolj\u0161ana QoL kod Uznapredovale Bolesti (Kolorektalni Karcinom):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> U studiji koja je procjenjivala Visokofrekventnu Hipertermiju potpomognutu kemoterapijom kod pacijenata s kolorektalnim karcinomom srednjeg i uznapredovalog stadija, grupa koja je primila kombinaciju pokazala je zna\u010dajno vi\u0161e (pobolj\u0161ane) QoL rezultate nakon 4 ciklusa lije\u010denja, dokazuju\u0107i da HT u\u010dinkovito pobolj\u0161ava QoL, uz terapeutske u\u010dinke, uz zadr\u017eavanje bolje sigurnosti .[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvantne Biolo\u0161ke Prednosti i Superiorni Terapijski Indeks<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksimizira letalnost lije\u010denja bez zna\u010dajnog pove\u0107anja rizika od te\u0161ke toksi\u010dnosti (Stupanj 3-4), \u010dime se odr\u017eava visok Terapijski Indeks:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Validirana Sigurnost (Faza III klini\u010dka ispitivanja):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-analize u raku vrata maternice pokazuju nema zna\u010dajne razlike u akutnoj ili kasnoj toksi\u010dnosti (RR Toksi\u010dnost 1.01)[6]. Sigurnosni profil odr\u017eava se kod Raka Rektuma [7] i u ispitivanjima Raka Gu\u0161tera\u010de[8].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">O\u010duvanje Organa:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Kod Raka Rektuma, dodavanje HT-a neoadjuvantnoj kemoradioterapiji pove\u0107ava 5-godi\u0161nje Pre\u017eivljenje Bez Kolostome (CFS) sa 69,0 % na 87,7 %, \u0161to je velika funkcionalna QoL korist.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abskopalni Efekt (Sli\u010dan Cjepivu):<\/strong> HT pokre\u0107e imunogenu stani\u010dnu smrt, osloba\u0111aju\u0107i Proteine Toplinskog \u0160oka (HSPs) koji aktiviraju citotoksi\u010dne CD8+ T stanice. Ovo sustavno imunolo\u0161ko poticanje doprinosi kontroli rezidualne bolesti i klju\u010dna je adjuvantna prednost.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zaklju\u010dak: Terapija Usredoto\u010dena na Pacijenta<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integracija Hipertermije u onkolo\u0161ki protokol predstavlja naprednu, na dokazima temeljenu strategiju koja ne samo da pobolj\u0161ava Pre\u017eivljenje, ve\u0107 pru\u017ea i robusnu kontrolu simptoma i odr\u017eava Kvalitetu \u017divota. Ubla\u017eavanje boli, kontrola umora i izvrstan sigurnosni profil \u010dine HT bitnim elementom holisti\u010dke skrbi za onkolo\u0161ke pacijente.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pozivamo vas da se posavjetujete s na\u0161im stru\u010dnjacima za integraciju Hipertermije u va\u0161 protokol, s ciljem maksimiziranja i u\u010dinkovitosti i Kvalitete \u017divota.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT Jamstvo:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ovaj sadr\u017eaj temelji se na objavljenim podacima iz randomiziranih i prospektivnih klini\u010dkih ispitivanja Faze III, koriste\u0107i standardizirane instrumente za mjerenje Kvalitete \u017divota (EORTC QLQ-C30). Pune reference integrirane su s izravnim poveznicama na izvorne publikacije.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reference:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritet i Stru\u010dnost (EEAT): Autor: Dr. Veronica Iatan , MD, i Cristian Gologan M.Sc , Andromedichyperthermia Utjecaj hipertermije na kvalitetu \u017eivota (QoL): Ubla\u017eavanje boli, smanjenje umora i adjuvantne imunolo\u0161ke prednosti U modernoj onkologiji, lije\u010denje raka te\u017ei optimalnoj ravnote\u017ei izme\u0111u Pre\u017eivljenja (OS\/DFS) i Kvalitete \u017divota (QoL). Hipertermija (HT) predstavlja jedinstvenu adjuvantnu modalitetu, dokazanu kroz velika klini\u010dka&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[871,33,117],"tags":[1057,872,873,1056,874,157,746,877,878],"class_list":["post-11435","post","type-post","status-publish","format-standard","hentry","category-studii-clinice-hr","category-uncategorized-hr","category-vijesti","tag-bol-hr","tag-calitatea-vietii-hr","tag-durere-hr","tag-faza-iii-klinicko-ispitivanje","tag-hipertermie-oncologica-hr","tag-hipertermija","tag-onkologija-hr","tag-qol-hr","tag-studii-faza-iii-hr"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/posts\/11435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/comments?post=11435"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/posts\/11435\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/media?parent=11435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/categories?post=11435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/hr\/wp-json\/wp\/v2\/tags?post=11435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}